Skip to content
StockMarketAgent
Direct answer
UnitedHealth Group is a dominant, diversified healthcare compounder with massive scale across its Optum and UnitedHealthcare segments. Despite recent acute margin pressure from elevated medical costs and Medicare Advantage rate headwinds, its integrated model provides highly durable, cycle-agnostic long-term cash flow generation. Fair value range: low $230, high $450, with mid-point at $340.
Stock analysis

UNH UnitedHealth Group Incorporated fair value $340–$450

UNH
By StockMarketAgent.AI team· supervised by
분석일: 2026-05-08다음 업데이트: 2026-08-08Methodology v2.4Archetype: Mature compounderNYSE · Health Care
View archive
주가
$378.06
▼ -38.07 (-10.07%)
공정 가치
$340
$340–$450
등급
비중 축소
confidence 88/100
상승 여력
-10.1%
upside to fair value
안전 마진
$288.99
buy below · 15%
시가총액
$343.3B
P/E fwd 18.2
영어 원본으로 대체KO
번역하는 동안 영어 원본을 표시 중
이 리포트는 아직 번역되지 않았습니다. 번역 대기열이 따라잡으면 몇 분 후에 새로고침하세요.

§1 개요

  • UNH offers unmatched scale in healthcare but currently faces acute near-term margin pressure.
  • Valuation models heavily cap aggressive extrapolations, yielding a grounded $339.99 fair value.
  • The current price of $378.07 embeds growth expectations that risk a multiple de-rating.
Fair value
$340
Margin of safety
-11.2%
Confidence
88/100
Moat
9/10

Educational analysis only — not financial advice. Always do your own due diligence.

$378.07Price
FV $339.99
High $449.63

UnitedHealth Group is a dominant, diversified healthcare compounder with massive scale across its Optum and UnitedHealthcare segments. Despite recent acute margin pressure from elevated medical costs and Medicare Advantage rate headwinds, its integrated model provides highly durable, cycle-agnostic long-term cash flow generation.

  • Cycle upside
    Favorable regulatory environments, stable utilization rates, and rapid adoption of value-based care.

§2 베어 케이스

A severe stress test assumes operating margins structurally compress to 4.2% without recovery, dragging ROICROICReturn on invested capital. Operating profit (after tax) divided by invested capital. The single best gauge of capital-efficiency. Spread over WACC = economic value created. below WACCWACCWeighted average cost of capital. The blended after-tax discount rate applied to free cash flows in a DCF, reflecting both equity and debt financing costs. and stalling free cash flow generation indefinitely.

이 논제가 무너지는 경로

Permanent MA Rate Cuts

· Medium

Regulatory agencies structurally enforce severe Medicare Advantage rate cuts, permanently destroying UNH margin profiles.

FV impact
Severe reduction to the low-end $230 fair value range.
Trigger
12-24 months

Runaway Medical Inflation

· Medium

Utilization rates remain permanently elevated while value-based care initiatives fail to offset the structural MCR deterioration.

FV impact
Midpoint collapses below $300 due to EPS and FCF stagnation.
Trigger
6-18 months

Antitrust Optum Breakup

· Low

Aggressive regulatory intervention forces the spin-off or severe operational firewalling of Optum from UnitedHealthcare.

FV impact
Sustained multiple compression and loss of integrated scale synergies.
Trigger
36-60 months
모니터링할 조기 경보 신호
지표현재트리거 임계값
Medical care ratio consistently exceeds the 84% threshold.MonitorDeterioration versus the report thesis
Optum Health revenue growth decelerates below 5% annually.MonitorDeterioration versus the report thesis
Operating margins fail to breach the 6% normalized assumption.MonitorDeterioration versus the report thesis
Regulatory changes successfully cap Medicare Advantage profitability.MonitorDeterioration versus the report thesis
Free cash flow conversion persistently drops below net income.MonitorDeterioration versus the report thesis

§3 재무 이력

손익계산서 — 최근 6기
항목T−0T−1T−2T−3T−4CAGR
기간2021-12-312022-12-312023-12-312024-12-312025-12-31Trend
매출$287.60B$324.16B$371.62B$400.28B$447.57B+11.7%
매출총이익$69.65B$79.62B$90.96B$89.40B$82.92B+4.5%
영업이익$23.97B$28.44B$32.36B$32.29B$18.96B-5.7%
순이익$17.29B$20.12B$22.38B$14.41B$12.06B-8.6%
EPS (희석)$18.08$21.18$23.86$15.51$13.23-7.5%
EBITDA$27.07B$31.84B$36.33B$28.08B$23.06B-3.9%
R&D
판관비

품질 점수

Piotroski F-스코어
6 / 9
0–9 품질 종합
Altman Z-스코어
2.97
파산 위험 (>3 안전)
OCF / 순이익
1.63×
>1은 이익의 질이 높음을 의미
회계 품질 게이트
Pass
섹터 조정 게이트
ROIC
8.6%
투하자본수익률
섹션 3

Numbers analysis

개인 구독자 — §4부터11개 섹션 더

전체 분석 읽기 — 11개 섹션 더.

Competitive moat, industry cycle, peer comparison, intrinsic valuation, sensitivity, scenarios, earnings decision tree, position management, investor perspectives, scorecard, and final recommendation.

모든 커버 종목에 대한 전체 보고서
24개월 등급 아카이브
관심 목록 브리핑 + 등급 변경 알림
모든 언어로 PDF + DOCX 내보내기
무료 체험 시작
언제든지 취소 가능.
FAQ

UNH — frequently asked questions

  1. Based on our latest independent analysis, UNH screens modestly overvalued. The current price is $378 versus a composite fair-value midpoint of $340 (range $230–$450), which implies roughly 10.1% downside to the midpoint.
Related coverage

Names readers of UNH also follow

Same archetype: mature-compounder
Same sector: Health Care